 |
Prospector
Profile
07.1659
|
| |
| CNS Response, Inc. |
NAICS |
518210 |
| 2755 Bristol St., Suite 285
Costa Mesa, CA 92626 |
Description |
Data Processing Services |
| (714) 545-3288 |
Employees |
9 |
| http://www.cnsresponse.com/physicianinfo.htm |
Revenue |
(mil) |
0.2380 |
| |
Income |
(mil) |
-3.2790 |
| |
Assets |
(mil) |
6.0120 |
| |
Liability |
(mil) |
0.6590 |
| |
(for the year ended 2007-09-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Cacciamatta Accountancy Corporation expressed substantial doubt about the ability of CNS Response, Inc., to continue as a going concern after auditing the company's consolidated financial statements for the year ended Sept. 30, 2007. The auditing firm pointed to the company's continued operating losses and limited capital. CNS Response posted a net loss of $3,279,100 on $238,400 of revenues for the year ended Sept. 30, 2007, as compared with a net income of $82,600 on $175,500 of net revenues in the prior year. At Sept. 30, 2007, the company's balance sheet showed $6,012,400 in total assets, $659,300 in total liabilities and $5,353,100 stockholders' equity.
|
| |
|
Intellectual Property:
The Company has two issued U.S. Patents which provide them exclusive rights to the rEEG technology. In addition, these patents cover the analytical methodology utilized by the Company with any form of neurophysiology measurement. It has also filed patent applications for the technology in various foreign jurisdictions.The Company has filed trademark applications in the United States for the marks Referenced-EEG and rEEG. The Company's rEEG Outcomes Database consists of approximately 13,000 clinical outcomes across 2,000 patients who had psychiatric or addictive problems. It considers the rEEG Outcomes Database to be a valuable trade secret and are diligent about protecting such information. [SEC Filing 10-KSB 12-07-07]
|
| |
|
Description:
The Company's business is focused on the commercialization of a patented system that aids physicians in the identification and determination of appropriate and effective medications for patients with certain behavioral disorders.
|
| |
|
Officers:
Leonard J. Brandt (CEO); George Carpenter (Pres.); Horace Hertz (CFO); David B. Jones (Dir.); Jerome Vaccaro, M.D. (Dir.); Kevin R. Keating (Dir.); Henry T. Harbin, M.D. (Dir.)
|
| |
|
Auditor:
Cacciamatta Accountancy Corporation
|
| |
|
Securities:
Common Stock-Symbol CNSO.OB; OTC BB;
25,299,547 common shares outstanding as of December 5, 2007.
|
| |
| |
| |
| return to main page |
|
|
